Trandolapril
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Trandolapril
| |
| Systematic (IUPAC) name | |
| (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl- propyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole- 2-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | C09 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C24H34N2O5 |
| Mol. mass | 430.537 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | Trandolapril 80% (independent of concentration) Trandolaprilat 65 to 94% (concentration-dependent) |
| Metabolism | Hepatic |
| Half life | 6 hours (trandolapril) 10 hours (trandolaprilat) |
| Excretion | Fecal and renal |
| Therapeutic considerations | |
| Pregnancy cat. |
D(US) |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For patient information, click here
Overview
Trandolapril is an ACE inhibitor used to treat high blood pressure, it may also be used to treat other conditions. It is marketed by Abbott Laboratories with the brand name Mavik®.
Pharmacology
Trandolapril is a prodrug that is deesterified to trandolaprilat. It is believed to exert its antihypertenive effect through the renin-angiotensin-aldosterone system. Trandolapril has a half life of about 6 hours, and trandolaprilat has a half life of about 10. Trandolaprilat has about 8 times the activity of its parent drug. Approximately 1/3 of Trandolapril and its metabolites are excreted in the urine, and about 2/3 of Trandolapril and its metabolites are excreted in the feces. Serum protein binding of trandolapril is about 80%.
Mode of action
Trandolapril acts by competitive inhibition of Angiotensin Converting Enzyme (ACE), a key enzyme in the renin-angiotensin system (RAS pathway) which plays an important role in regulating blood pressure. See ACE inhibitors for more information.
Side effects
Side effects reported for Trandolapril include nausea, vomiting, or diarrhea; headache; dry cough; dizziness or lightheadedness when sitting up or standing; hypotension or fatigue.
Possible Drug Interactions
Patients also on diuretics may experience an excessive reduction of blood pressure after initiation of therapy with Trandolapril. Trandolapril can reduce potassium loss caused by thiazide diuretics, and increase serum potassium when used alone. Therefore hyperkalemia is a possible risk. Increased serum lithium levels can occur in patients who are also on lithium. For more information see angiotensin converting enzyme (ACE) inhibitors.
Contraindications and Precautions
See ACE inhibitors for more information.
Pregnancy and Lactation
Category D
Trandolapril is teratogenic and can cause birth defects and even death of the developing fetus. The highest risk to the fetus is during the second and third trimester. When pregnancy is detected, Trandolapril should be discontinued as soon as possible.
Trandolapril should not be administed to nursing mothers.
External links
- Mavik (PDF from manufacturer's website)
- Tarka (PDF from manufacturer's website)
- Trandolapril (patient information)
- Trandolapril Information - rxlist.com (Rxlist.com, The Internet Drug Index)
References
- Trandolapril Information - rxlist.com (Rxlist.com, The Internet Drug Index)
Agents acting on the renin-angiotensin system (C09) | |
|---|---|
| ACE inhibitors | Benazepril • Captopril • Delapril • Enalapril • Fosinopril • Imidapril • Lisinopril • Moexipril • Perindopril • Quinapril • Ramipril • Spirapril • Temocapril • Trandolapril • Zofenopril |
| Angiotensin II receptor antagonists (AIIRA) | Candesartan • Eprosartan • Irbesartan • Losartan • Olmesartan • Tasosartan • Telmisartan • Valsartan |
| Renin inhibitors | Aliskiren • Remikiren |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
